Company intelligence / Profile preview

Impakt Therapeutics

Shanghai, Shanghai, China

Ownership: Private
Development stage: Other

Overview

Senaparib (IMP4297) PARP inhibitor is approved by China’s NMPA for maintenance treatment of advanced ovarian cancer post first-line therapy; demonstrated best-in-class efficacy and safety in Phase III FLAMES study. IMP7068 (Wee1) and IMP9064 (ATR) are in Phase I; PARP1-selective IMP1734 has IND clearance.

Therapeutic areas: Oncology
Modalities: Small molecule
Industry: Biotech

Partnerships

Eikon Therapeutics (PARP1 selective inhibitor IMP1734)

Beyond the preview

Go deeper on Impakt Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Impakt Therapeutics.

Explore the full profile